Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
The new project further expands the partner's long-term collaboration on new technologies for R&D
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Subscribe To Our Newsletter & Stay Updated